Features of the pathogenesis and course of myocardial infarction in COVID-19 patients: a descriptive review
https://doi.org/10.15829/1728-8800-2022-3270
Abstract
The coronavirus disease 2019 (COVID-19) pandemic remains one of the most urgent problems for healthcare professionals due to the variety of non-pulmonary manifestations. Along with the respiratory syndrome in a significant proportion of patients, the disease course is accompanied by pronounced systemic inflammatory response and hemostasis changes. This is associated with a high risk of complications, especially in patients with concomitant cardiovascular pathology. The aim of the study was to analyze and systematize the literature data on the pathogenesis, clinical course, and outcomes of myocardial infarction (MI) in patients with COVID-19. For review, publications indexed in the PubMed, Google Scholar, Web of Science, and Cyberleninka databases were used. The search depth was 2 years, starting from 2020. The review is based on summarized data from the most relevant clinical studies, reports and systematic reviews. The literature analysis made it possible to conclude that the published data on MI in patients with COVID-19 are currently contradictory. Multiple thrombosis, sepsis, macrophage activation, increasing hypoxemia, imbalance between myocardial oxygen supply and demand in patients with severe COVID-19 have led to a high incidence of type 1 and type 2 MI. It should be especially noted that in a number of cases, MI with COVID-19 occurs in patients with intact coronary arteries, and its course is associated with a high incidence of complications, which, in turn, leads to a significant increase in short- and mid-term mortality.
About the Authors
M. G. Chashchin
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Moscow.
A. Yu. Gorshkov
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Moscow.
A. V. Strelkova
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
Moscow.
O. M. Drapkina
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Moscow.
References
1. Solomon MD, McNulty EJ, Rana JS, et al. The Covid-19 Pandemic and the Incidence of Acute Myocardial Infarction. N Engl J Med. 2020;383:691-3. doi:10.1056/NEJMC2015630.
2. De Filippo O, D’Ascenzo F, Angelini F, et al. Reduced Rate of Hospital Admissions for ACS during COVID-19 Outbreak in Northern Italy. N Engl J Med. 2020;383:88-9. doi:10.1056/NEJMC2009166.
3. Wu J, Mamas M, Rashid M, et al. Patient response, treatments, and mortality for acute myocardial infarction during the COVID-19 pandemic. Eur Hear J — Qual Care Clin Outcomes. 2020;0:1-9. doi:10.1093/ehjqcco/qcaa062.
4. Papafaklis MI, Katsouras CS, Tsigkas G, et al. “Missing” acute coronary syndrome hospitalizations during the COVID-19 era in Greece: Medical care avoidance combined with a true reduction in incidence? Clin Cardiol. 2020;43:1142-9. doi:10.1002/CLC.23424.
5. Bhatt AS, Moscone A, McElrath EE, et al. Fewer Hospitalizations for Acute Cardiovascular Conditions During the COVID-19 Pandemic. J Am Coll Cardiol. 2020;76:280-8. doi:10.1016/J.JACC.2020.05.038.
6. D’Ascenzo F, De Filippo O, Borin A, et al. Impact of COVID-19 pandemic and infection on in hospital survival for patients presenting with acute coronary syndromes: A multicenter registry. Int J Cardiol. 2021;332:227-34. doi:10.1016/J.IJCARD.2021.03.063.
7. Matsushita K, Hess S, Marchandot B, et al. Clinical features of patients with acute coronary syndrome during the COVID-19 pandemic. J Thromb Thrombolysis. 2020:1-10. doi:10.1007/s11239-020-02340-z.
8. Morishita T, Takada D, Shin J, et al. Trends, Treatment Approaches, and In-Hospital Mortality for Acute Coronary Syndrome in Japan During the Coronavirus Disease 2019 Pandemic. J Atheroscler Thromb. 2021; 29(5):597-607 doi:10.5551/JAT.62746.
9. Braiteh N, Rehman W ur, Alom M, et al. Decrease in acute coronary syndrome presentations during the COVID-19 pandemic in upstate New York. Am Heart J. 2020;226:147-51. doi:10.1016/j.ahj.2020.05.009.
10. Solano-López J, Zamorano JL, Pardo Sanz A, et al. Risk factors for in-hospital mortality in patients with acute myocardial infarction during the COVID-19 outbreak. Rev Esp Cardiol. 2020;73:985-93. doi:10.1016/j.rec.2020.07.009.
11. Druzhinin PV, Molchanova EV. Mortality Rates in Russian Regions in the Context of the COVID-19 Pandemic. Regionology. 2021;29:666-85. (In Russ.) doi:10.15507/2413-1407.116.029.202103.666-685.
12. Campo G, Fortuna D, Berti E, et al. In- and out-of-hospital mortality for myocardial infarction during the first wave of the COVID-19 pandemic in Emilia-Romagna, Italy: A population-based observational study. Lancet Reg Heal — Eur. 2021;3:100055. doi:10.1016/J.LANEPE.2021.100055.
13. Marijon E, Karam N, Jost D, et al. Out-of-hospital cardiac arrest during the COVID-19 pandemic in Paris, France: a population-based, observational study. Lancet Public Heal. 2020;5:e437-43. doi:10.1016/S2468-2667(20)30117-1.
14. Lim ZJ, Ponnapa Reddy M, Afroz A, et al. Incidence and outcome of out-of-hospital cardiac arrests in the COVID-19 era: A systematic review and meta-analysis. Resuscitation. 2020;157:248-58. doi:10.1016/j.resuscitation.2020.10.025.
15. Hanff TC, Mohareb AM, Giri J, et al. Thrombosis in COVID-19. Am J Hematol. 2020;95:1578-89. doi:10.1002/AJH.25982.
16. Tajbakhsh A, Gheibi Hayat SM, Taghizadeh H, et al. COVID-19 and cardiac injury: clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up. Expert Review of Antiinfective Therapy. 2020;19:345-57. doi:10.1080/14787210.2020.1822737.
17. Choudry FA, Hamshere SM, Rathod KS, et al. High Thrombus Burden in Patients With COVID-19 Presenting With ST-Segment Elevation Myocardial Infarction. J Am Coll Cardiol. 2020;76:1168-76. doi:10.1016/j.jacc.2020.07.022.
18. Dominguez-Erquicia P, Dobarro D, Raposeiras-Roubín S, et al. Multivessel coronary thrombosis in a patient with COVID-19 pneumonia. Eur Heart J. 2020;41:2132. doi:10.1093/EURHEARTJ/EHAA393.
19. Tedeschi D, Rizzi A, Biscaglia S, et al. Acute myocardial infarction and large coronary thrombosis in a patient with COVID-19. Catheter Cardiovasc Interv. 2020:ccd.29179. doi:10.1002/ccd.29179.
20. Tersalvi G, Vicenzi M, Calabretta D, et al. Elevated Troponin in Patients With Coronavirus Disease 2019: Possible Mechanisms. J Card Fail. 2020;26:470-5. doi:10.1016/J.CARDFAIL.2020.04.009.
21. Long B, Brady WJ, Koyfman A, et al. Cardiovascular complications in COVID-19. Am J Emerg Med. 2020;38:1504-7. doi:10.1016/J.AJEM.2020.04.048.
22. Khan IH, Zahra SA, Zaim S, et al. At the heart of COVID-19. J Card Surg. 2020;35:1287-94. doi:10.1111/JOCS.14596.
23. Sandoval Y, Januzzi JL, Jaffe AS. Cardiac Troponin for Assessment of Myocardial Injury in COVID-19: JACC Review Topic of the Week. J Am Coll Cardiol. 2020;76:1244-58. doi:10.1016/J.JACC.2020.06.068.
24. Loghin C, Chauhan S, Lawless SM. Pseudo-Acute Myocardial Infarction in a Young COVID-19 Patient. JACC Case Reports. 2020;2:1284-8. doi:10.1016/J.JACCAS.2020.04.015.
25. Barbarash OL, Duplyakov DV, Zateischikov DA, et al. 2020 Clinical practice guidelines for Acute coronary syndrome without ST segment elevation. Russian Journal of Cardiology. 2021;26(4):4449. (In Russ.) doi:10.15829/1560-4071-2021-4449.
26. Mahajan K, Chandra KS. Cardiovascular comorbidities and complications associated with coronavirus disease 2019. Med J Armed Forces India. 2020;76:253-60. doi:10.1016/J.MJAFI.2020.05.004.
27. Halushka MK, Vander Heide RS. Myocarditis is rare in COVID-19 autopsies: cardiovascular findings across 277 postmortem examinations. Cardiovasc Pathol. 2021;50:107300. doi:10.1016/J.CARPATH.2020.107300.
28. Khalid N, Chen Y, Case BC, et al. COVID-19 (SARS-CoV-2) and the Heart — An Ominous Association. Cardiovasc Revascularization Med. 2020;21:946-9. doi:10.1016/J.CARREV.2020.05.009.
29. AL Abbasi B, Torres P, Ramos-Tuarez F, et al. Cardiac Troponin-I and COVID-19: A Prognostic Tool for In-Hospital Mortality. Cardiol Res. 2020;11:398-404. doi:10.14740/cr.1159.
30. Gaze DC. Clinical utility of cardiac troponin measurement in COVID-19 infection. Ann Clin Biochem. 2020;57:202-5. doi:10.1177/0004563220921888.
31. Chapman AR, Bularga A, Mills NL. High-Sensitivity Cardiac Troponin Can Be an Ally in the Fight against COVID-19. Circulation. 2020;141:1733-5. doi:10.1161/CIRCULATIONAHA.120.047008.
32. Rashid M, Wu J, Timmis A, et al. Outcomes of COVID-19-positive acute coronary syndrome patients: A multisource electronic healthcare records study from England. J Intern Med. 2021;290:88-100. doi:10.1111/JOIM.13246.
33. Pepe M, Frati G, Biondi-Zoccai G, et al. Direct and indirect effects of COVID-19 on acute coronary syndromes: Can we pick the worst? Int J Cardiol. 2021;335:19-20. doi:10.1016/J.IJCARD.2021.04.036.
Supplementary files
Review
For citations:
Chashchin M.G., Gorshkov A.Yu., Strelkova A.V., Drapkina O.M. Features of the pathogenesis and course of myocardial infarction in COVID-19 patients: a descriptive review. Cardiovascular Therapy and Prevention. 2022;21(7):3270. (In Russ.) https://doi.org/10.15829/1728-8800-2022-3270
Views:
1007
Email this article 
